NEOSTIGMINE METHYLSULFATE (neostigmine) by Dr. Reddy's Laboratories is inhibitor. First approved in 2018.
Drug data last refreshed 18h ago
inhibitor. By reducing the breakdown of acetylcholine, neostigmine methylsulfate induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as non-depolarizing neuromuscular blocking agents, and reverses the neuromuscular blockade.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial
Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery
Influence of Neostigmine vs. Sugammadex on PORC and PPCs by Ultrasonography
Comparison of Time to Extubation Using Sugammadex or Neostigmine
Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery
Worked on NEOSTIGMINE METHYLSULFATE at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.